Science

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors

Sameer Rastogi/X

May 31, 2025, 12:57

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors

Sameer Rastogi, Additional Professor of Sarcoma and GIST Medical Oncology Clinic at AIIMS, New Delhi, shared a post on X:

“We are pleased to share the preliminary results of SORASTOP, which investigates whether sorafenib can be discontinued in individuals with desmoid tumors who are responding to treatment. Good early results.”

Title: Clinico-radiological outcomes of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders – early results from the SORASTOP study

Authors: Bharath B Gangadharaiah, Ghazal Tansir, Sameer Rastogi, Simran Kaur, Vikas Garg, Ekta Dhamija, Adarsh Barwad, Shivanand Gamanagatti, Sandeep Bhoriwal and Maroof A Khan

Read Full Article on ecancer.

SORASTOP

Further Reading:

Sorafenib (Nexavar): Uses in Cancer, Side Effects, Dosage, Expectations, and More

Sorafenib (Nexavar): What patients need to know?

Adarsh Barwad Bharath B Gangadharaiah cancer Ekta Dhamija Ghazal Tansir Maroof A Khan OncoDaily Oncology Sameer Rastogi Sandeep Bhoriwal Shivanand Gamanagatti Simran Kaur SORASTOP Trial Vikas Garg

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect